Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

William J. Kostis; Milton Packer; Henry R. Black; Roland E. Schmieder; David Henry; Elliott Levy

doi:10.1016/j.amjhyper.2003.09.014

Abstract

Omapatrilat provided broadly superior antihypertensive efficacy when used in a setting resembling clinical practice. Angioedema was more common than with enalapril but life-threatening angioedema was rare. The risk-benefit profile for omapatrilat in clinical use therefore appears likely to be favorable in appropriate patients.

Keywords

EnalaprilMedicineACE inhibitorRandomized controlled trialInternal medicineDiureticBlood pressureCombination therapyCardiologyAngiotensin-converting enzyme

Affiliated Institutions

Related Publications

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

Laxminarayan G. Hegde , Cecile Yu , Travis Renner +11 more

Dual inhibition of angiotensin-converting enzyme (ACE) and neprilysin (NEP) by drugs such as omapatrilat produces superior antihypertensive efficacy but cause high incidence of ...

2011 Journal of Cardiovascular Pharmacology 63 citations

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

Carlos M. Ferrario , Jewell A. Jessup , Mark C. Chappell +5 more

Background— Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vaso...

2005 Circulation 1598 citations

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedema

Ryan M. Fryer , Jason A. Segreti , Patricia N. Banfor +8 more

Background and purpose: Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clinical trial in patients administered the ...

2007 British Journal of Pharmacology 129 citations

Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure

Milton Packer , Robert M. Califf , Marvin A. Konstam +4 more

Background— Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alon...

2002 Circulation 623 citations

Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.

The present study enrolled 214 patients, aged 26 to 83 years, with symptomatic New York Heart Association class II through IV congestive heart failure. Patients were continued o...

1996 The American Journal of Cardiology 482 citations

Publication Info

Year: 2004
Type: article
Volume: 17
Issue: 2
Pages: 103-111
Citations: 577
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

577

OpenAlex

Cite This

APA Style

                            
                                
                                    William J. Kostis, 
                                
                                    Milton Packer, 
                                
                                    Henry R. Black
                                
                                et al.
                            
                            (2004). 
                            Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. 
                            American Journal of Hypertension
                            , 17
                            (2)
                            , 103-111.
                            https://doi.org/10.1016/j.amjhyper.2003.09.014
                        

Identifiers

DOI: 10.1016/j.amjhyper.2003.09.014